ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

ClinicalTrials.gov ID: NCT03122522

Public ClinicalTrials.gov record NCT03122522. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 8:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

Study identification

NCT ID
NCT03122522
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Enrollment
70 participants

Conditions and interventions

Interventions

  • ipilimumab Drug
  • nivolumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 16, 2017
Primary completion
Mar 31, 2027
Completion
Mar 31, 2027
Last update posted
May 5, 2026

2017 – 2027

United States locations

U.S. sites
14
U.S. states
6
U.S. cities
11
Facility City State ZIP Site status
Hartford Healthcare Alliance (Data Collection Only) Hartford Connecticut 06102
Jaykumar Thumar Hartford Connecticut 06102
JOHNS HOPKINS HOSPITAL (Data Analysis Only) Baltimore Maryland 21287
Brigham and Women's Hospital (Data and Specimen Analysis Only) Boston Massachusetts 02115
Memorial Sloan Kettering Basking Ridge Basking Ridge New Jersey 07920
Memorial Sloan Kettering Monmouth Middletown New Jersey 07748
Memorial Sloan Kettering Bergen Montvale New Jersey 07645
Memorial Sloan Kettering Commack Commack New York 11725
Memorial Sloan Kettering Westchester Harrison New York 10604
Hospital for Special Surgery (Data Analysis) New York New York 10021
Columbia University (Data Analysis Only) New York New York 10032
Memorial Sloan Kettering Cancer Center New York New York 10065
Memorial Sloan Kettering Nassau Uniondale New York 11553
Lehigh Valley Health Network (Data Collection Only) Allentown Pennsylvania 18103

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03122522, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 5, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03122522 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →